The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Results of Phase II study of bomedemstat in myelofibrosis
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China discusses the results from an open label, 24 week Phase II study (NCT03136185) investigating the use of the orally active, irreversible lysine-specific demethylase-1 (LSD1) inhibitor bomedemstat for the treatment of myelofibrosis (MF). Dr Gill comments on the multiple outcome measures which were assessed, including reduction in spleen volume from baseline, total symptoms score, the impact on inflammatory cytokine levels, mutant allele frequencies, and hemoglobin levels. Overall, the results show that bomedemstat appears to be an effective and well-tolerated drug for patients with advanced MF after first-line therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Oncology – honoraria, consultancies; Celgene/bms – research grant, honoraria, consultancies; PharmaEssentia – research grant; Abbvie – honoraria, consultancies; Takeda – honoraria; Pfizer Oncology – honoraria, consultant
